Drug intelligence / Profile preview

leptospira vaccine

Development stage: Unknown
Lead developer: Wuhan Institute of Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Leptospira vaccine, developed by the Wuhan Institute of Biological Products (WIBP), is an inactivated vaccine indicated for the active immunization against leptospirosis. Leptospirosis is a widespread zoonotic disease caused by pathogenic spirochetes of the genus *Leptospira*. The vaccine is typically composed of inactivated whole-cell cultures of various *Leptospira* serovars, such as *Leptospira interrogans*, which are prevalent in the target region. It is administered via intramuscular injection to stimulate the production of protective antibodies, thereby reducing the incidence and severity of the disease in high-risk populations. The product is approved for use in China.

Other names: 钩端螺旋体疫苗Leptospirosis vaccine

Beyond the preview

Go deeper on leptospira vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on leptospira vaccine.

Explore the full profile